Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Magnesium SCHEMBL9306977 | 0.98 | TAAR1 (0.41) | TAAR1TSHRALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL8168961 | 0.94 | ALDH1A1 (0.40) | TAAR1TSHRALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6650386 | 0.91 | TAAR1 (0.40) | TAAR1TSHRALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL3995603 | 0.83 | TAAR1 (0.43) | TAAR1TSHRALDH1A1CYP2A6L3MBTL1 | |
| SCHEMBL22613508 | 0.81 | ALDH1A1 (0.45) | TSHRALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL10627557 | 0.81 | CYP2A6 (0.41) | TAAR1TSHRALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL2082178 | 0.79 | LMNA (0.42) | TSHRALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL1934134 | 0.78 | TSHR (0.36) | TSHRALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2084415 | 0.77 | LMNA (0.54) | TSHRALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9047543 | 0.77 | TSHR (0.38) | TSHRALDH1A1SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344858-B2 | Micro-electrolysis reactor for ultra fast, oxidant free, C—C coupling reaction and synthesis of daclatasvir analogs thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2022-05-31 | — | — | US | claimed |
| CN-113402350-A | Biaryl compound and preparation method and application thereof | 南京工业大学 | 2021-09-17 | — | — | CN | claimed |
| US-20200346182-A1 | MICRO-ELECTROLYSIS REACTOR FOR ULTRA FAST, OXIDANT FREE, C-C COUPLING REACTION AND SYNTHESIS OF DACLATASVIR ANALOGS THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-11-05 | — | — | US | claimed |
| US-12521395-B2 | Gem-disubstituted heterocyclic compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2026-01-13 | — | — | US | disclosed |
| EP-4055015-B1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-04-02 | — | — | EP | disclosed |
| US-20230000871-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-01-05 | — | — | US | disclosed |
| CN-113402350-B | Biaryl compound and preparation method and application thereof | 南京工业大学 | 2022-11-11 | — | — | CN | disclosed |
| EP-4055015-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2022-09-14 | — | — | EP | disclosed |
| CN-115038700-A | Gem disubstituted heterocyclic compounds and their use as IDH inhibitors | 内尔维亚诺医疗科学公司 | 2022-09-09 | — | — | CN | disclosed |
| US-11344858-B2 | Micro-electrolysis reactor for ultra fast, oxidant free, C—C coupling reaction and synthesis of daclatasvir analogs thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2022-05-31 | — | — | US | disclosed |
| US-11344858-B2 | Micro-electrolysis reactor for ultra fast, oxidant free, C—C coupling reaction and synthesis of daclatasvir analogs thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2022-05-31 | — | — | US | disclosed |
| EP-0073447-B1 | PROCESS FOR PRODUCING 1-(P-PRENYLPHENYL)ETHANOL | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1984-11-21 | — | — | EP | disclosed |
| US-4436939-A | Process for producing 1-(p-prenylphenyl)ethanol | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1984-03-13 | — | — | US | disclosed |
| EP-0073447-A1 | Process for producing 1-(p-prenylphenyl)ethanol | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1983-03-09 | — | — | EP | disclosed |
| US-4251543-A | ANTIINFLAMMATORY AGENTS, ANALGESICS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1981-02-17 | — | — | US | disclosed |
| US-4051261-A | HYPOLIPIDEMIC, ANTIDIABETIC | SANDOZ, INC. (US) | 1977-09-27 | — | — | US | disclosed |
| US-4004026-A | Dicarboxylic acids and derivatives in the treatment of pain and inflammation | CIBA-GEIGY CORPORATION (US) | 1977-01-18 | — | — | US | disclosed |
| US-3953525-A | α-Substituted-4-(2,2-dimethyl-1-hydroxypropyl)benzyl alcohols and esters | SANDOZ, INC. (US) | 1976-04-27 | — | — | US | disclosed |
| US-3944589-A | α-Cycloalkenylphenyl-fatty acid nitriles | CIBA-GEIGY CORPORATION (US) | 1976-03-16 | — | — | US | disclosed |
| US-3940434-A | ANTIINFLAMMATORY, ANALGESIC | CIBA-GEIGY CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344858-B2 | Micro-electrolysis reactor for ultra fast, oxidant free, C—C coupling reaction and synthesis of daclatasvir analogs thereof | CYCS, COASY, CAT | TAAR1 2443/4885TSHR 3455/4885ALDH1A1 532/4885 |
| US-20230000871-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | IDH1, IDH2, IDH3A | TAAR1 4787/4885TSHR 4759/4885ALDH1A1 478/4885 |
| US-20200346182-A1 | MICRO-ELECTROLYSIS REACTOR FOR ULTRA FAST, OXIDANT FREE, C-C COUPLING REACTION AND SYNTHESIS OF DACLATASVIR ANALOGS THEREOF | CYCS, COASY, CAT | TAAR1 2456/4885TSHR 3484/4885ALDH1A1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.